It is a weak base (pKa 7.8) with poor oral bioavailability thus necessitating administration of relatively high doses (300–450 mg/kg body weight in preclinical models) for optimal therapeutic benefits (Aneja et al., 2007; Ke et al., 2000; Ye et al., 1998).